K2 HealthVentures (K2HV) is an alternative investment firm providing flexible, long-term debt, equity, and convertible financing solutions to innovative private and public companies in the life sciences and healthcare industries.
75% of their portfolio is in Healthcare. Deal activity increased 100% year-over-year (6 deals in the last 12 months). Average disclosed round size is $84.3M (across 20 rounds with reported amounts).
Portfolio
16
Fund Size
$400M
Top Stage
Series D
Last 12 Mo
6
Team
Luis Viera
Managing Director,Portfolio Management
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
20 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Hopscotch | Series D | $53M | Aug 2026 |
 Hopscotch Primary Care | Series D | $53M | Aug 2026 |
 Honest Health | Growth | $140M | Feb 2026 |
 Honest Health | Unknown | $140M | Feb 2026 |
 Zarminali Pediatrics | Series A | $110M | Jan 2026 |
 Apella Technology | Series B | $80M | Jan 2026 |
| Hopscotch | Series D | $53M | Jan 2026 |
 Phil, Inc. | Growth | $60M | Jul 2025 |
 Umoja | Series C | $100M | Jan 2025 |
 Evergreen Nephrology | Series D | $130M | Jan 2025 |
 Umoja Biopharma | Series C | $100M | Jan 2025 |
 HarmonyCares | Series D | $200M | Jul 2024 |
 Vedanta Biosciences | Series D | $40M | Jan 2024 |
| Hopscotch | Seed | $3.6M | Oct 2021 |
 Cricket Health | Series B | $83.5M | Aug 2021 |
 Click Therapeutics | Series B | $48.5M | Jan 2021 |
| Click Therapeutics | Series A | $17M | Jan 2018 |
 VBI Vaccines | Unknown | $100M | — |
 Mighty Therapeutics | Series B | $125M | — |
| Hopscotch Primary Care | Series C | $50M | — |
Top Co-Investors
Oak HC/FT5 shared
8VC5 shared
Rubicon Founders4 shared
Alumni Ventures3 shared
aMoon3 shared
India Quotient3 shared
Citi Impact Fund3 shared
General Catalyst2 shared
Valtruis2 shared
Cormorant Asset Management2 shared
Qiming Venture Partners USA2 shared
Alexandria Venture Investments2 shared
CaaS Capital2 shared
Double Point Ventures2 shared
MPM Capital2 shared
Durable Capital Partners2 shared
Welsh, Carson, Anderson & Stowe2 shared
NewSpring2 shared
GG12 shared
Revelation Partners2 shared
Last updated: 7 October 2026